Extra Caution Needed In Uncertain Period For Off-Label Info Distribution
This article was originally published in The Gray Sheet
Executive Summary
Until FDA finalizes guidance on what practices are acceptable in distributing journal articles that describe off-label product indications, companies should watch their step in avoiding investigations that could lead to fines, criminal prosecution or exclusion from federal reimbursement programs, attorneys say
You may also be interested in...
Waxman’s Legislative Powers On The Rise: How Much Will Fall On MedTech?
Rep. Henry Waxman's new perch atop the House Energy and Commerce Committee gives the aggressive lawmaker at least as much leverage as he has recently enjoyed on the investigative front, but more authority to follow through with legislation
Waxman’s Legislative Powers On The Rise: How Much Will Fall On MedTech?
Rep. Henry Waxman's new perch atop the House Energy and Commerce Committee gives the aggressive lawmaker at least as much leverage as he has recently enjoyed on the investigative front, but more authority to follow through with legislation
Post-Election Industry Outlook: New User Fees, More Aggressive FDA
With a Democrat-controlled government led by President-elect Barack Obama poised to take control, industry experts have begun speculating on the future of device regulation and reimbursement